Bio waiver for lower strength (250mg) Mycophenolate mofetil tablet [Regulatives / Guidelines]

posted by jag009  – NJ, 2019-11-07 20:52 (1626 d 17:54 ago) – Posting: # 20762
Views: 2,819

Hi,

❝ Please, I would like to know that, with the In vitro comparative dissolution study report can we waive off BE In vivo study with in vitro comparative dissolution study for the lower strength for Mycophenolate mofetil tablet 250mg or do we require separate BE study for the lower strength.


Are the strengths formulation proportional? FDA or EMA?

❝ And also I would like to know that whether similar approach can be taken for all the pro-drug where the metabolite of the drug is pharmacologically active.


FDA yes. Take a look at enalapril BE guidance.

J

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,650 registered users;
31 visitors (1 registered, 30 guests [including 5 identified bots]).
Forum time: 15:47 CEST (Europe/Vienna)

As soon as we abandon our own reason, and are content
to rely upon authority, there is no end to our troubles.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5